GV20 Therapeutics
GV20 Therapeutics discovers and develops antibody therapeutics targeting cancer immunology to advance new immuno-oncology treatments. The company combines high-throughput functional genomics and AI-driven analysis with a proprietary antibody drug discovery engine to identify novel targets and generate antibody candidates. GV20 operates as a drug discovery and development biotech (B2B model) focused on immuno-oncology, with sites in Cambridge, USA and Shanghai. Its platform supports building a pipeline of antibody drug candidates against novel and difficult targets for partnering or clinical development.
GV20 Therapeutics
GV20 Therapeutics discovers and develops antibody therapeutics targeting cancer immunology to advance new immuno-oncology treatments. The company combines high-throughput functional genomics and AI-driven analysis with a proprietary antibody drug discovery engine to identify novel targets and generate antibody candidates. GV20 operates as a drug discovery and development biotech (B2B model) focused on immuno-oncology, with sites in Cambridge, USA and Shanghai. Its platform supports building a pipeline of antibody drug candidates against novel and difficult targets for partnering or clinical development.